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AbstrAct
background: the aim was to demonstrate the feasibility and technique of gonadal sparing total body irradiation (tBi) with 
helical tomotherapy. total body irradiation is a common part of the conditioning regimen prior to allogeneic stem cell trans-
plantation. Shielding or dose-reduction to the gonads is often desired to preserve fertility, particularly in young patients 
undergoing transplant for non-malignant indications. helical tomotherapy (ht) has been shown to be superior to traditional 
tBi delivery for organ at risk (oaR) doses and dose homogeneity.
Materials and methods: We present two representative cases (one male and one female) to illustrate the feasibility of this 
technique, each of whom received 3Gy in a single fraction prior to allogeneic stem cell transplant for benign indications. the 
planning target volume (PtV) included the whole body with a subtraction of oaRs including the lungs, heart, and brain (each 
contracted by 1cm) as well as the gonads (testicles expanded by 5 cm and ovaries expanded by 0.5 cm). 
results: For the male patient we achieved a homogeneity index of 1.35 with a maximum and median planned dose to the 
testes of 0.53 Gy and 0.35 Gy, respectively. in-vivo dosimetry demonstrated an actual received dose of 0.48 Gy. For the female 
patient we achieved a homogeneity index of 1.13 with a maximum and median planned dose to the ovaries of 1.66 Gy and 
0.86 Gy, respectively.
conclusion: Gonadal sparing tBi is feasible and deliverable using ht in patients with non-malignant diseases requiring tBi as 
part of a pre-stem cell transplant conditioning regimen.
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introduction
Total body irradiation (TBI) is commonly used 
in patients undergoing allogenic stem cell trans-
plantation for both malignant and benign pro-
cesses. Both traditional TBI approaches (opposed 
lateral and AP/PA) use extended source to skin dis-
tances (SSDs), custom compensators, blocks, and 
beam spoilers to ensure adequate skin dose [1]. 
However, traditional linear accelerator-based deliv-
ery has several limitations, including dose-limiting 
toxicity [2, 3]. For men, attempts to use a “clam-
shell” testicular shield may increase dose due to 
increased electron scatter [4]. More recently, volu-
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metric modulated arc therapy (VMAT) has been 
used for better dose distributions on standard lin-
ear accelerators, but this method can become overly 
complex with multi-isocentric setups and extended 
planning and delivery times [5]. The advantages of 
helical tomotherapy (HT)-based TBI include radial 
delivery of dose [6], creating better dose distribu-
tion, increased conformity and homogeneity, and 
image guidance, without the need for the above 
modifiers or compacted patient positioning (lateral 
technique) [7]. 
An unmet need in TBI is the ability to spare 
dose to the gonads, which can be technically chal-
lenging in full grown adolescents or young adults. 
Radiotherapy can cause temporary azoospermia at 
low doses and recovery of spermatogenesis may 
take up to 30 months after a single dose of 2–3 Gy 
and up to 5 years with a dose of 4 Gy [8]. Although 
azoospermia can become permanent after 6–8 Gy 
in 2-Gy fractions [9], the LD50 of the human oocyte 
is < 2 Gy, potentially leading to permanent steril-
ity in women [10]. Based on previous reports on 
HT-TBI feasibility and fertility preservation needs, 
we used HT in two young adults undergoing 3Gy 
TBI in preparation for allogeneic transplant for the 
treatment of severe sickle cell anemia.
Materials and methods
A 20-year old man with severe sickle beta-zero 
thalassemia and a 32-year old woman with severe 
sickle cell anemia both underwent conditioning 
with alemtuzumab and a single fraction of TBI to 
3Gy prior to matched allogeneic transplants. Pa-
tient height precluded AP/PA TBI with lead or ce-
ramide-block shielding. We, therefore, investigated 
the ability to deliver TBI using HT for gonadal 
sparing using a TomoTherapy H unit (Accuray, 
Inc., Sunnyvale, CA).
ct simulation
Immobilization was achieved using a vacuum 
cushion (BlueBAG BodyFIX, Elekta AB, Stock-
holm, Sweden) and a custom thermoplastic mask 
in a supine position with arms by the side. An 
initial CT scan was completed head-first from the 
vertex through the mid femur and a second scan 
was completed feet-first for the remainder of the 
lower extremities, both with a slice thickness of 
3mm. Due to the field length limitations of our 
HT unit (up to 160 cm), two image sets were used 
to generate two HT plans, with a match line de-
lineated at the mid femur with radiographically 
opaque wire well below the level of the genitals to 
avoid hotspots.
organs at risk (oaRs)  
and target volumes
The brain, lungs, heart, kidneys, and gonads 
were delineated as OARs. Avoidance structures 
of each of these organs were created as follows: 
the brain, lungs, and heart were each contracted 
by 1cm, the kidneys were unchanged, the testicles 
were expanded by 5cm, and the ovaries were ex-
panded by 0.5cm and contracted out of the bony 
pelvis + 1cm (Fig. 1A, 2A). The lungs and heart 
were contracted to ensure the rib cage remained 
within the treatment target volume during normal 
respiratory motion. We did not include the liver 
as an avoidance structure, given the potential for 
Kupffer cells or other immune infiltrates. How-
ever, the exclusion of the liver from target volumes 
would not be unreasonable. 
The clinical target volume (CTV) was defined 
as the whole body minus the gonadal avoidance 
structures, lungs, heart, and brain. This was then 
expanded by 1 cm and the avoidance structures 
(brain — 1 cm, lungs/heart — 1 cm, kidneys, testes 
+5 cm, ovaries +0.5 cm) were subtracted to create 
the planning target volume (PTV). 
tBi planning
An HT plan for TBI was generated for these 
patients with 96% of the PTV being covered by the 
prescription dose of 3 Gy using a field width of 5 
cm and a standard grid size (Fig. 1B, 2B). Planning 
proceeded as described by Hui et al. [11]. Briefly, 
TERMA (total energy released per unit mass) opti-
mizations were performed to find the lowest modu-
lation factor (MF) and the loosest pitch capable of 
maintaining the dose–volume histogram character-
istics of a plan with a high MF and tight pitch while 
achieving a reasonable total treatment time [11]. 
This resulted in an MF and a pitch of 2 and 0.330, 
respectively, for the first plan and a pitch of 2 and 
MF of 0.303 for the second. Approximately 15–20 
optimizations were needed to view the result of the 
constraint adjustment, which took 45–60 minutes. 
The same jaw width, pitch, and MF were used for 
the lower extremity plans.
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Quality assurance (Qa)
For QA, a 3D diode array cylindrical phantom 
was imaged (Delta4, Scandidos Uppsala, Sweden) 
[12] on the CT simulator scanner and imported 
into the TomoTherapy planning station. The patient 
treatment plans were transferred onto the phantom 
image and dose distribution based on the phantom 
material and geometry was calculated. The gamma 
(3%, 3 mm) passing rate criteria between the calcu-
lated and measured plans was set at 90%. Because 
of the size of the PTVs, two QA plans were applied 
to the phantom (head first and feet first).
a B
Figure 2. A. ovarian avoidance structure. b. isodose distribution. 3 Gy was prescribed to 95% of the planning target volume 
(PtV).
a B
Figure 1. A. testicular avoidance structure. b. isodose distribution. 3 Gy was prescribed to 95% of the planning target volume 
(PtV)
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treatment delivery
Prior to treatment delivery, four megavoltage 
computed tomography (MVCT) scans were ob-
tained in the treatment position in the coarse mode 
(head, thorax, pelvis, feet). Automatic kVCT to 
MVCT fusion was performed on the basis of these 
regions of interest. Manual fusion was performed 
to improve the registration accuracy by verifying 
axial, coronal and sagittal images. This entire pro-
cess took 15–20 minutes. Once the registration was 
approved, the couch was positioned to the deter-
mined registration coordinates and treatment was 
delivered. 
Results
For the first case, the overall beam-on time was 
approximately 43 minutes. The maximum and me-
dian doses to the testes were 0.53 Gy and 0.35 Gy, 
respectively (Tab. 1). The in-vivo dosimetry was cal-
culated using the NanoDotTM (Landauer, Glenwood, 
IL) and confirmed that the testes received 0.48 Gy. 
Based on the in-vivo dosimetry, the difference be-
tween planned and delivered doses ranged from 
–17.8% to 14.6% (Tab. 2). The second case achieved 
maximum and median doses to the ovaries of 1.66 
Gy and 0.86 Gy, respectively (Tab. 1). In-vivo dosim-
etry of the ovaries was not feasible, but the differ-
ence between planned and delivered doses to other 
areas ranged from –26.1% to 43.6% (Tab. 2). 
Both patients successfully underwent bone mar-
row transplant after completion of the condition-
ing regimen. They were both discharged after an 
uneventful hospital course. The first patient’s most 
recent follow-up was 25 months after transplant 
and unremarkable. The second patient’s most recent 
follow-up was 3 months after transplant and unre-
markable as well.
Discussion
To the authors’ knowledge, we describe the first 
technical report of using HT-TBI to provide go-
nadal sparing in full-grown adults for non-malig-
nant conditions. With HT, there is no need to use 
heavy blocks, beam spoilers, an extended source 
to skin distance, or uncomfortable patient posi-
tioning. The ability to reduce the delivered dose 
to the testes to 0.48Gy will nearly eliminate the 
risk of long-term azoospermia [9] and maintain-
ing the maximum delivered dose to the ovaries to 
1.66 Gy will greatly reduce the risk of premature 
ovarian failure [10]. Conversely, when clinical 
scenarios require boosting the gonads [13], HT 
could easily be used to deliver a simultaneous 
integrated boost. This method lies within a spec-
trum of techniques between traditional TBI to 
more focused total marrow irradiation (TMI) and 
total marrow and lymph node irradiation (TMLI). 
Although the latter hold promise to reduce toxic-
ity and dose escalation targets, availability and 
implementation are quite heterogeneous [14] and 
may involve higher dose rates, potentially increas-
ing toxicity, or high marrow doses, increasing the 
risk of nonengraftment [13]. While this method 
conceptually shifts toward TMI, the continued 
difference in targets serves to distinguish the two 
methods.
table 1. achieved doses for organs at risk based off of the planned dosimetry
OAR
Planned dosimetry
Case 1 Case 2
Max dose (Gy) Median dose (Gy) Mean dose (Gy) Max dose (Gy) Median dose (Gy) Mean dose (Gy)
lungs 3.58 3.14 3.06 3.39 2.28 2.22
heart 3.53 2.82 2.8 3.04 1.08 1.22
testicles 0.53 0.35 0.36 n/a n/a n/a
testicles + 5 cm 3.09 0.55 0.69 n/a n/a n/a
ovary n/a n/a n/a 1.66 0.86 0.89
adnexa n/a n/a n/a 2.48 0.95 1.03
Right kidney 3.48 3.26 3.27 2.94 1.15 1.37
left kidney 3.39 3.22 3.22 2.93 1.12 1.25
oaR — organ at risk; n/a — non available
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Total body irradiation continues to be a critical 
tool in bone marrow transplantation to decrease 
tumor burden in malignant diseases and to sup-
press the recipient’s immune system to improve the 
likelihood of graft rejection [15]. This report also 
demonstrates the homogeneity and image guid-
ance abilities of HT-TBI, in contrast to classic TBI 
with dose variations of up to 50% due to thickness 
difference at different level of the body [16]. In our 
representative cases, the homogeneity indices were 
1.35 and 1.13, respectively. 
conclusion
In this Technical Report, we demonstrate the fea-
sibility and potential benefits of using HT-TBI over 
traditional methods. Future research is warranted 
to explore potential benefits of targeted TBI, both 
in the optimal approach for transplantation and 
special circumstances as described in this report.
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